Outcomes in patients with Mycobacterium abscessus pulmonary disease treated with long-term injectable drugs

https://doi.org/10.1016/j.rmed.2010.12.012Get rights and content
Under an Elsevier user license
open archive

Summary

Background

The ATS (American Thoracic Society) has recommended periodic administration of multidrug therapy, including a macrolide and one or more parenteral agents or a combination of parenteral agents, over 2–4 months, for treatment of Mycobacterium abscessus pulmonary disease. However, there is little hard evidence supporting these guidelines, and treatment outcomes have not yet been reported.

Methods

We retrospectively evaluated 41 patients with M. abscessus pulmonary disease treated in accordance with ATS guidelines. These patients were treated empirically with multidrug regimens, including a macrolide and one (amikacin) or more (amikacin and cefoxitin or imipenem) parenteral agents, over several months. Treatment outcomes were defined as treatment success, failure, or default.

Results

Seventeen (41.5%) patients were prescribed a macrolide and one parenteral agent, and 24 (58.5%) were prescribed a macrolide and two parenteral agents. The median duration of parenteral and total antibiotic treatment were 230 days (range, 60–601 days) and 511 days (range, 164–1249 days), respectively. The treatment success, failure, and default rates were 80.5% (33/41), 12.2% (5/41), and 7.3% (3/41), respectively. Four patients relapsed over 445 days (range, 0–1443 days) of follow-up. There were no significant differences in treatment success and relapse rates between the groups receiving one and two parenteral agents. Adverse reactions developed in 18 of 41 patients (43.9%).

Conclusions

Combination antibiotic therapy, including long-term (minimum 2–4 months) parenteral drugs, as recommended by the ATS, resulted in successful treatment outcomes in 80.5% of patients with M. abscessus lung disease in Korea.

Keywords

Atypical mycobacteria
Lung diseases
Mycobacterium abscessus
Treatment outcome

Abbreviations

ATS
American Thoracic Society
DILI
drug-induced liver injury
NTM
nontuberculous mycobacteria
MAC
Mycobacterium avium-intracellulare complex
TB
tuberculosis
AFB
acid-fast bacilli
PCR
polymerase chain reaction
DST
drug susceptibility test
CXRs
chest radiographs
CT
computed tomography
MICs
minimum inhibitory concentrations

Cited by (0)

Institution at which the work was performed: Asan Medical Center.